Oncology

Clinical takeaway

Oncology applications of cells and EVs range from established marrow reconstitution to investigational tissue repair, tumor microenvironment modulation, biomarkers, and drug delivery. Each conclusion must remain matched to the exact product, cancer or treatment complication, biological objective, route, comparator, endpoint, and follow-up. [1-12]

Biological rationale

Relevant mechanisms include hematopoietic reconstitution, graft-versus-tumor immunity, immunomodulation, trophic signaling, angiogenesis, extracellular-matrix remodeling, molecular-cargo transport, and gene silencing. The same broad biological property can have different consequences in injured normal tissue and an active tumor. [1,2,5,11]

Product identity

Autologous and allogeneic hematopoietic grafts, culture-expanded MSCs, gene-modified immune cell or hematopoietic products, native EV preparations, and engineered EVs are not interchangeable. Source cell, donor relationship, manufacturing process, cargo, potency, purity, and release criteria are part of product identity. [1,2,4,8,11]

Preclinical evidence

Preclinical models support MSC trafficking, context-dependent tumor interactions, EV biomarker discovery, and engineered-cargo delivery. Translation depends on model immunology, tumor architecture, product exposure, biodistribution, dose, timing, and whether the measured outcome represents mechanism, tumor control, or normal-tissue repair. [5,6,8,11]

Human clinical evidence

HSCT is established for selected hematologic malignancies and some solid-tumor settings. A randomized MSC trial in radiation-related hyposalivation showed improved dry-mouth symptoms but no superiority for objective salivary flow. Remestemcel-L is approved for a defined transplant complication. EV biomarkers have favorable pooled diagnostic signals in some cancers, and engineered EV delivery has reached Phase I testing with early feasibility and target-engagement findings. [1-4,9-12]

Trial design

Oncology trials should prespecify cancer type, molecular subtype, disease burden, prior and concurrent therapy, product identity, dose, route, timing, comparator, patient-important endpoints, tumor-response criteria, tissue-injury outcomes when applicable, surveillance for recurrence or secondary malignancy, and adequate follow-up. Biomarker studies require locked assays and independent validation sets. [2,3,8-12]

Dose and administration

Intravenous hematopoietic grafts, intraglandular MSC injections, and intravenous engineered EVs differ in target tissue, biodistribution, exposure, and dose units. Cell number, viability, body-weight adjustment, vesicle count or protein and cargo amount, schedule, conditioning regimen, and concomitant therapy should be specified. [1-4,11,12]

Safety

Assessment should address infusion and procedure reactions, fever, infection, immune effects, graft failure, graft-versus-host disease, organ toxicity, thrombosis, ectopic tissue, product persistence, genomic or phenotypic instability, tumor growth or recurrence, secondary malignancy, and off-target EV distribution. The relevant risks depend on the platform and clinical setting. [1-8,11-14]

Regulatory status

Regulatory status is product-, indication-, route-, jurisdiction-, and date-specific. The United States has approved defined hematopoietic, immune-cell, and MSC products for specified uses. FDA states that exosome products intended to treat disease generally require approval; its current approved-product list includes no exosome product. Engineered oncology EV products remain investigational. Approval status and efficacy evidence should be reported separately. [2,4,13-15]

Standard care

Standard care depends on cancer type and may include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, established HSCT, symptom-directed treatment, rehabilitation, and survivorship care. Investigational repair, biomarker, or EV-delivery approaches should be evaluated against the appropriate contemporary comparator. [1-4,16]

Knowledge gaps

Major gaps include predictive tumor and host features, long-term oncologic safety after reparative cell therapy, mechanisms that determine tumor-supporting versus tumor-inhibiting stromal effects, standardized EV isolation and dose metrics, scalable manufacturing, validated potency assays, tumor-specific biodistribution, and randomized evidence for engineered EV efficacy. [3,5-14]

Bottom-line evidence statement

Oncology contains both established cell-based treatment and early translational applications. HSCT provides established marrow reconstitution and, in allogeneic settings, graft-versus-tumor activity for defined indications. MSCs have a favorable symptom signal but a null physiological primary outcome in a randomized radiation-injury trial, while laboratory evidence identifies plausible tumor-supporting mechanisms that have not been established as a uniform clinical effect. EV biomarkers show promising diagnostic performance in selected reviews, and engineered EV delivery has favorable Phase I feasibility data without comparative efficacy confirmation. [1-15]

Evidence summary

Additional controlled terminology

A liquid biopsy evaluates tumor-associated material in a body fluid. Sensitivity is the proportion of people with the target condition whom a test identifies as positive; specificity is the proportion without the condition whom it identifies as negative. Target engagement demonstrates that an intervention interacted with its intended biological target; it is not identical to clinical benefit. A dose-limiting toxicity is an adverse effect that prevents further dose escalation under a study protocol.